Titlebook: Current and Emerging Therapies in Pancreatic Cancer; Tanios Bekaii-Saab,Bassel El-Rayes Book 2018 Springer International Publishing AG 201

凹槽

Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed,poor outcomes despite recent advances in chemotherapeutic approaches. Gemcitabine therapy has been the standard first-line treatment for patients with unresectable locally advanced or metastatic pancreatic cancer until recent studies showed improved outcomes with chemotherapy combinations, albeit wi

curriculum

PAC

盡管

Synthetic Lethality: Achilles Heel in Select Patient Subpopulations,re one such event is survivable. Mutations in BRCA1/2 or homologous recombination genes lead to dependency on alternative low-fidelity DNA repair mechanisms. Inhibition of the alternative pathways, such as with a PARP inhibitor, can lead to cancer cell death in preclinical models..Up to 15% of pancr

blight

Immunotherapies in Pancreatic Cancer,hus, most of the focus has been on implementing new drugs and therapeutic approaches in the metastatic setting. As the effect of cytotoxic agents has plateaued, immunotherapeutic interventions have emerged, in an attempt to improve the prognosis in this dismal disease. A better understanding of the

新手

Vaccine Therapy in Pancreatic Cancer,the armamentarium of therapeutics for this disease. Vaccines represent an important method to train the body’s own immune system to attack pancreatic cancer cells. Despite a number of unique targets on pancreatic cancer cells, vaccines have been largely ineffective at prolonging survival in pancreat

Plaque

macrophage

過度

The Role for Palliative Surgical Interventions in Pancreatic Cancer,patients present with biliary obstruction, gastric outlet obstruction, and malignant bowel obstruction secondary to tumor burden and local invasion. While surgery has been utilized liberally to treat these conditions, more recent evidence emphasizing palliation, decreased hospital length of stay, an

pessimism

https://doi.org/10.1007/978-3-319-58256-6cystic pancreatic lesions; resectable disease; non-metastatic disease; cytotoxic therapy; JAK/Stat pathw